Immunology in the Clinic Review Series; focus on metabolic diseases: Development of islet autoimmune disease in type 2 diabetes patients: Potential sequelae of chronic inflammation

Clinical and Experimental Immunology

Volumn 167, Issue 1, 2012, Pages 40-46

  Brooks Worrell, B ^a   Palmer, J P ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; Diabetes; Inflammation inflammatory mediators including eicosanoids; T cells

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; DIABETIC PATIENT; HUMAN; IMMUNOLOGY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

ACUTE-PHASE REACTION; ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CHRONIC DISEASE; CYTOKINES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; ISLETS OF LANGERHANS; MODELS, IMMUNOLOGICAL; OBESITY; RATS; SELF TOLERANCE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 82655171679     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04501.x     Document Type: Review

References (79)

1. Jager A, Kuchroo VK. Effector and regulatory T cell subsets in autoimmunity and tissue inflammation. Scand J Immunol 2010; 72:173-84.
2. null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res 2009; 81:11-19.
3. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99.
4. Zamarron BF, Chen WJ. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011; 7:651-8.
5. Goverman J, Brabb T, Paez A, Harrington C, von Dassow P. Initiation and regulation of CNS autoimmunity. Crit Rev Immunol 1997; 17:469-80.
6. Burns J, Rosenzwerg A, Zwerman B, Lisak RP. Isolation of myelin basic protein-reactive T cell lines from normal human blood. Cell Immunol 1983; 81:435-40.
7. Homann D, von Herrath M. Regulatory T cells and type 1 diabetes. Clin Immunol 2004; 112:202-9.
8. Hoyne GF. Mechanisms that regulate peripheral immune responses to control organ-specific autoimmunity. Clin Dev Immunol 2011; 2011:294968 Epub 2011 28 April.
9. Bubanovic I. Auto-immunity as evolutionary by product of adoptive immunity and source of anti-tumor immunity failure. Int J Cancer Res 2005; 1:81-6.
10. Brooks-Worrell B, Palmer JPP. Is diabetes mellitus a continuous spectrum? Clin Chem 2011; 57:158-61.
11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20:1183-97.
12. McCance DR, Hanson RL, Pettitt DF, Bennett PH, Hadden DR, Knowler WC. Diagnosing diabetes mellitus: do we need new criteria? Diabetologia 1997; 40:247-55.
13. Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt2+ T cells. J Exp Med 1987; 166:823-32.
14. Miller BJ, Appel MC, O'Neil JJ, Wicker LS. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 1988; 140:52-8.
15. Lampeter EF, Homberg M, Quabeck K etal. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993; 341:1243-4.
16. Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch Physiol Biochem 2009; 115:240-7.
17. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes. Diabetes Care 2008; 31:S161-4.
18. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology 2009; 24:325-31.
19. Boni-Schnetzler M, Ehses JA, Faulenbach M, Donath MY. Insulitis in type 2 diabetes. Diabetes Obes Metab 2008; 10:S20-S204.
20. Kintscher U, Hartge M, Hess K etal. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008; 28:1304-10.
21. Nishimura S, Manabe I, Nagasaki M etal. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009; 15:914-20.
22. Winer S, Chan Y, Paltser G etal. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009; 15:921-9.
23. Wu H, Ghosh S, Perrard XD etal. T-cell accumulation and regulation on activation, normal T cell expressed and secreted up-regulation in adipose tissue in obesity. Circulation 2007; 115:1029-38.
24. Feuerer M, Herrero L, Cipolletta D etal. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameter. Nat Med 2009; 15:930-40.
25. Deiuliis J, Shah Z, Shah N etal. Visceral adipose inflammation in obesity is associated with critical alterations in T regulatory cell numbers. PLoS ONE 2011; 6:e16376. doi:10.1371/journal.pone.0016376.
26. Ilan Y, Maron R, Tukpah A-M etal. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci 2010; 107:9765-70.
27. Meijer K, de Vries M, Al-Lahham S etal. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PLoS ONE 2011; 6:e17154. doi: 10.1371/journal.pone.0017154.
28. Spranger J, Kroke A, Mohlig M etal. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam study. Diabetes 2003; 52:812-17.
29. Herder C, Brunner EJ, Rathmann W etal. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32:421-3.
30. Pradhan DA, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin-6 and risk of developing type 2 diabetes mellitus. JAMA 2001; 286:327-34.
31. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11:98-107.
32. Larsen CM, Faulenbach M, Vaag A etal. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-26.
33. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152:346-57.
34. Jager J, Gremeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1β-induced insulin resistance in adipocytes through down-relation of insulin receptor substrate-1 expression. Endocrinology 2007; 148:241-51.
35. Weigert C, Hennige AM, Lehmann R etal. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 2006; 281:7060-7.
36. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.
37. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity induced insulin resistance in mice lacking TNF-α function. Nature 1997; 389:610-14.
38. Lee MS. Role of innate immunity in diabetes and metabolism: recent progress in the study of inflammasomes. Immune Netw 2011; 11:95-9.
39. Pickup JC. Inflammation and activation innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27:813-23.
40. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, an the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167:1670-5.
41. Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gasteroenterol Hepatol 2006; 4:482-8.
42. Deckert M, Sanchez-Ruiz M, Brunn A, Schluter D. Role of CD8 T-cell-mediated autoimmune diseases of the central nervous system. Crit Rev Immunol 2010; 30:311-26.
43. Mars LT, Saikali P, Liblau RS, Arbour N. Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. Biochim Biophys Acta 2011; 1812:151-61.
44. Zierden M, Kuhnen E, Odenthal M, Dienes HP. Effects and regulation of autoreactive CD8+ T cells in a transgenic mouse model of autoimmune hepatitis. Gasteroenterology 2010; 139:975-86.
45. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Adaptive immunity in autoimmune hepatitis. Dig Dis 2010; 28:63-9.
46. Faustman DL, Davis M. The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies. J Mol Med 2009; 87:1173-8.
47. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25:821-52.
48. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223:87-113.
49. Winer S, Paltser G, Chan Y etal. Obesity predisposes to TH17 bias. Eur J Immunol 2009; 39:2629-35.
50. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Auto-immune inflammation from the Th17 perspective. Autoimmun Rev 2007; 6:169-75.
51. Cnop M, Welsh N, Jonas J-C, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes. Diabetes 2005; 545 (Suppl. 2):S97-S107.
52. Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 2003; 66:1433-40.
53. DeFronzo RA, Tipathy D, Schwenke DC etal. for the ACT NOW study. Pioglitazone for Diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364:1104-15.
54. Seyfert-Margolis V, Gisler TD, Asare AL etal. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006; 55:2588-94.
55. Herold KC, Brooks-Worrell B, Palmer JPP etal. The type 1 diabetes TrailNet research group: validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009; 58:2588-95.
56. Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JPP. Peripheral blood mononuclear cells of insulin-dependent diabetic patients: respond to multiple islet cell proteins. J Immunol 1996; 157:5668-74.
57. Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JPP. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J Immunol 2001; 166:5265-70.
58. Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JPP. Cellular immune response to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999; 48:983-8.
59. Brooks-Worrell BM, Reichow JL, Goel A, Ismail H, Palmer JPP. Identification of autoantibody-negative autoimmune type 2 diabetes patients. Diabetes Care 2011; 34:168-73.
60. Goel A, Chiu H, Felton J, Palmer JPP, Brooks-Worrell B. T cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 2007; 56:2110-15.
61. Foryst-Ludwig A, Hertge M, Clemenz M etal. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol 2010; 9:64-72.
62. Wang J, Miao D, Babu S etal. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007; 92:88-92.
63. Nagata M, Moriyama H, Kotani R etal. Immunological aspects of 'fulminant type 1' diabetes. Diabetes Res Clin Pract 2007; 77:1-5.
64. Verge CF, Gianani R, Kawasake I etal. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type 1 diabetes. J Autoimmun 1996; 9:370-83.
65. Naserke HE, Ziegler A-G, Lampasona V, Bonifacio E. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 1998; 161:6963-9.
66. Kawasaki E, Yu L, Rewers MJ, Hutton JC, Eisenbarth GS. Definition of multiple ICA 512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes 1998; 47:733-42.
67. Greenbaum CJ, Brooks-Worrell BM, Palmer JPP, Lernmark A. Autoimmunity and prediction of insulin dependent diabetes mellitus. In: Marshal SM, Home PD, eds. The diabetes annual/8. Amsterdam: Elsevier, 1994:21-9.
68. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JPP. Islet cell antibodies and glutamic acid decarboxylase antibodies but not the clinical phenotype help to identify type 1 1/2 diabetes in patients presenting with type 2 diabetes. Metabolism 2001; 50:1008-13.
69. Mayer A, Fabien N, Gutowski MC etal. Contrasting cellular and humoral autoimmunity associated with latent autoimmune diabetes in adults. Eur J Endocrinol 2007; 157:53-61.
70. Zavala AV, Fabiano de Bruno LE, Cardoso AI etal. Cellular and humoral autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Diabetologia 1992; 35:1159-64.
71. Hosszufalusi N, Yatay A, Rajczy K etal. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003; 26:452-7.
72. Murao S, Kondo S, Ohashi J etal. Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA) - a 5 year follow-up of the Ehime study. Diabetes Res Clin Pract 2008; 38:114-21.
73. Wenzlau JM, Moua O, Sarkar SA etal. SIC30A8 is a major target of humoral autoimmunity in Type 1 diabetes and a predictive marker in prediabetes. Immunology of diabetes V. Ann NY Acad Sci 2008; 1150:256-9.
74. Seissler J, DeSonnaville JJJ, Morgenthaler NG etal. Immunological heterogeneity in type 1 diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998; 41:891-7.
75. Palmer JPP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005; 54:S62-67.
76. Abraham A, Donaghue KC, Chan AK, Benitez-Aguirre P, Lloyd M, Craig ME. Adiposity at diagnosis of childhood type 1 diabetes - have we reached a plateau? Diabetes 2011; 60:A43-44.
77. Klingensmith GJ, Kaminski BM, Diabetes P. Consortium: obesity and DKA are common in youth at T1D onset: findings of the pediatric diabetes consortium (PDC). Diabetes 2011; 60:A340.
78. Libman I, Hughan K, Giwa A, Lee S, Beker D, Arslanian S. Are overweight children with type 1 diabetes mellitus (T1DM) at increased risk of cardiovascular disease (CVD)? Diabetes 2011; 60:A333.
79. Faulkner MS, Michaliszyn SF, Going S, Wheeler MD. Body mass index and waist circumference are associated with C-reactive protein and heart rate variability in adolescents with Type 1 diabetes. Diabetes 2011; 60:A341.